The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Five-year results of a phase 2 trial using ipilimumab (I), nivolumab (N), and trabectedin (T) for previously untreated advanced soft tissue sarcoma (NCT03138161).
 
Erlinda Maria Gordon
Stock and Other Ownership Interests - Counterpoint Biomedica; Delta Next-Gene
Speakers' Bureau - AADi
Research Funding - Bristol Mers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of patents on targeting pharmaceutical agents to injured tissues
 
Sant P. Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Victoria S. Chua-Alcala
No Relationships to Disclose
 
Ted T. Kim
No Relationships to Disclose
 
Noufil Adnan
No Relationships to Disclose
 
Simranjit Sekhon
No Relationships to Disclose
 
Nicole Angel
No Relationships to Disclose
 
Mitchel Fernando
No Relationships to Disclose
 
Don Arlen Brigham
No Relationships to Disclose
 
Doris V. Quon
No Relationships to Disclose
 
Ania Moradkhani
No Relationships to Disclose
 
Steve Wong
No Relationships to Disclose